The peptide results are preclinical tests, not the same as human studies that we all want Generex to begin. I’m just noting because that’s not some game changer. That’s preclinical testing of a peptide sequence to move forward with. While it’s important for Generex in designing a vaccine, it’s not some big news that typically propels a stock.